What is HC Wainwright’s Forecast for LRMR Q2 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Analysts at HC Wainwright issued their Q2 2026 earnings per share (EPS) estimates for Larimar Therapeutics in a research report issued on Thursday, July 2nd. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.38) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.46) EPS, Q1 2027 earnings at ($0.42) EPS, Q2 2027 earnings at ($0.39) EPS and Q3 2027 earnings at ($0.36) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.22.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a report on Tuesday, April 21st. Citigroup reiterated a “buy” rating on shares of Larimar Therapeutics in a report on Tuesday. Truist Financial raised shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. JPMorgan Chase & Co. initiated coverage on Larimar Therapeutics in a report on Wednesday, May 27th. They set an “overweight” rating and a $9.00 price objective for the company. Finally, Robert W. Baird cut their target price on Larimar Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $12.71.

Larimar Therapeutics Price Performance

Shares of LRMR stock opened at $3.26 on Friday. The firm’s 50-day simple moving average is $3.67 and its 200-day simple moving average is $3.94. Larimar Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.42. The firm has a market cap of $338.66 million, a P/E ratio of -1.58 and a beta of 0.84.

Institutional Trading of Larimar Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Deerfield Management Company L.P. grew its holdings in Larimar Therapeutics by 44.2% during the 3rd quarter. Deerfield Management Company L.P. now owns 30,606,974 shares of the company’s stock worth $98,861,000 after acquiring an additional 9,375,000 shares in the last quarter. Blue Owl Capital Holdings LP grew its stake in Larimar Therapeutics by 16.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 6,823,690 shares of the company’s stock worth $25,998,000 after purchasing an additional 970,650 shares in the last quarter. Millennium Management LLC grew its stake in Larimar Therapeutics by 7.2% in the fourth quarter. Millennium Management LLC now owns 5,206,364 shares of the company’s stock worth $19,836,000 after purchasing an additional 349,533 shares in the last quarter. Opaleye Management Inc. increased its holdings in Larimar Therapeutics by 114.7% in the second quarter. Opaleye Management Inc. now owns 4,110,000 shares of the company’s stock valued at $11,878,000 after buying an additional 2,195,923 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in Larimar Therapeutics by 44.2% in the third quarter. Vanguard Group Inc. now owns 3,087,840 shares of the company’s stock valued at $9,974,000 after buying an additional 945,809 shares during the last quarter. 91.92% of the stock is owned by institutional investors and hedge funds.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.